CSL Behring has received approval from the US Food and Drug Administration (FDA) for the use of its recombinant factor VIII single-chain therapy, Afstyla, as a treatment for haemophilia A.

Hemophilia A is a congenital bleeding disorder that causes prolonged or spontaneous bleeding, especially into muscles, joints or internal organs.

Said to be the first and only single-chain product for the treatment of haemophilia A, Afstyla can protect the patient from bleeds.

The drug can be administered on patients for routine prophylaxis to reduce the frequency of bleeding episodes.

"The drug can be administered on patients for routine prophylaxis to reduce the frequency of bleeding episodes."

Using a covalent bond that forms one structural entity and a single polypeptide-chain, Afstyla improves the stability of factor VIII to provide longer-lasting factor VIII activity.

Besides controlling bleeding episodes, Afstyla can also be used for perioperative management of bleeding in adults and children with haemophilia A.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CSL chief scientific officer Dr. Andrew Cuthbertson said: "The approval of Afstyla, an innovative and effective haemophilia A therapy, further demonstrates CSL’s dedication to developing and delivering novel therapies that have the potential to improve patients’ lives.

"We are very excited to add this treatment to our industry-leading portfolio of coagulation therapies and look forward to the positive impact Afstyla can have on patients with haemophilia A."

The FDA approval is based on the drug’s efficacy results from Affinity clinical development programme, which involved two pivotal and one extension open-label multi-centre studies.

During the studies, adult and adolescent patients with haemophilia A were treated with Afstyla.